Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbiome composition and cellulolytic bacteria associated with the carpenter bee Xylocopa frontalis.

Applied microbiology and biotechnology·2026
Same author

Polarity-guided fractionation of Lippia alba ethanolic extract: Phytochemical profiling and correlation with antioxidant, enzyme-inhibitory, and antimicrobial and antiparasitic activity.

Fitoterapia·2026
Same author

Bacterial polar metabolites modulate β-amyloid toxicity and cholinergic dysfunction in models of Alzheimer's disease.

Scientific reports·2026
Same author

Pangenome Architecture and Accessory Gene-Driven Population Structure of <i>Staphylococcus aureus</i> Revealed by a Hospital-Adjacent Environmental Isolate.

Microorganisms·2026
Same author

Placental Growth Factor and Compromised Fetal Growth: Associations with Placental Ultrasound Morphology and Pathology in a Retrospective Cohort Study.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
Same author

Encapsulated Pterostilbene in pH-Sensitive Alginate Beads for LDL Oxidation Inhibition and Antioxidant Protection.

ACS omega·2026

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Lucas Matos Martins Bernardes1,2, Serena Mares Malta1,2, Matheus Henrique Silva1,2

  • 1Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

Mutated kefir-derived peptides (KDPs) show promise in preventing amyloid-beta (Aβ) aggregation, a key factor in Alzheimer

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Area of Science:

  • Biochemistry
  • Neuroscience
  • Pharmacology

Background:

  • Kefir contains probiotics and its fractions exhibit antioxidant and neuroprotective properties.
  • Amyloid-beta (Aβ) aggregation is a hallmark of Alzheimer's disease (AD).
  • Kefir-derived peptides (KDPs) were computationally modified to enhance Aβ binding and blood-brain barrier (BBB) penetration.

Purpose of the Study:

  • To design and evaluate mutated KDPs for their ability to inhibit Aβ plaque formation in vitro.
  • To assess the efficacy of modified KDPs in preventing or disrupting Aβ aggregation.

Main Methods:

  • In silico mutagenesis and peptide property prediction (ToxinPred, PeptideRanker, BBPpred).
  • Molecular docking of mutated KDPs (mKDPs) with Aβ monomers.
  • In vitro thioflavin T aggregation assay for early and late Aβ treatment with synthesized peptides.

Main Results:

  • All tested peptides demonstrated anti-Aβ aggregation effects in early treatment.
  • Mutated KDP2 showed the highest inhibition (56%) in early treatment, followed by digested KDP (dKDP) at 57%.
  • Mutated KDP1 and KDP2 significantly reduced Aβ aggregation in late treatment (approx. 45% inhibition).

Conclusions:

  • Mutated KDPs, particularly mKDP1 and mKDP2, effectively inhibit Aβ aggregation in vitro.
  • These findings suggest potential therapeutic applications for modified KDPs in Alzheimer's disease.
  • Further in vivo studies are required to confirm the efficacy and safety of these peptides.